Photoacoustic Imaging Patents

Photoacoustic imaging patents cover light-source/illumination innovations; transducer/detection innovations; reconstruction/imaging innovations; and contrast-agent and system/application innovations — with IP held by optoacoustic-imaging companies and medical-imaging firms (in a field of light-and-sound hybrid imaging). WHY PHOTOACOUSTIC IMAGING: 'PHOTOACOUSTIC IMAGING' (also 'optoacoustic imaging') is a hybrid method combining LIGHT and SOUND to see inside tissue with both rich optical CONTRAST and ultrasound-like DEPTH/resolution; a short LASER pulse illuminates the tissue; molecules (especially HEMOGLOBIN in blood) ABSORB the light, heat up infinitesimally, and rapidly expand, generating a tiny ULTRASOUND wave (the 'PHOTOACOUSTIC EFFECT'); ultrasound TRANSDUCERS detect these sound waves, and the signals are RECONSTRUCTED into an image; the key ADVANTAGE: pure optical imaging can't see deep (light SCATTERS in tissue within ~1 mm), and pure ultrasound lacks molecular/functional contrast — photoacoustics gets the BEST OF BOTH: the rich, molecule-specific contrast of light (e.g. distinguishing OXYGENATED vs DEOXYGENATED blood, mapping vessels and oxygenation) at the DEPTH and resolution of ultrasound (centimeters); this enables FUNCTIONAL and MOLECULAR imaging — measuring blood OXYGENATION (sO2), vascularity, and (with multiple wavelengths or CONTRAST AGENTS) specific molecules — non-invasively and WITHOUT ionizing radiation; APPLICATIONS: breast cancer characterization, oxygenation/perfusion mapping, vascular and inflammatory disease (e.g. Crohn's), and preclinical research; CHALLENGES: light PENETRATION DEPTH, signal/sensitivity, QUANTIFYING oxygenation accurately, real-time imaging, integrating with ultrasound, and clinical validation/regulatory; the HARD problems: the LIGHT SOURCE/illumination, the TRANSDUCER/detection, RECONSTRUCTION/imaging, CONTRAST AGENTS, and the SYSTEM/application. MAJOR PLAYERS: SENO MEDICAL, ITHERA MEDICAL, FUJIFILM/VISUALSONICS, plus optoacoustic and medical-imaging companies. Light source/illumination, transducer/detection, reconstruction/imaging, contrast agents, and system/application are the core photoacoustic-imaging patent domains — and light sources, transducers, reconstruction, contrast agents, and systems are the open whitespace. (Note: photoacoustics uniquely combines optical molecular/functional contrast (e.g. blood oxygenation) with ultrasound depth — its killer capability is non-invasive FUNCTIONAL/MOLECULAR imaging; depth, quantifying oxygenation, real-time imaging, and clinical validation are the challenges.)

Light-source/illumination innovations; transducer/detection innovations; multi-wavelength innovations; and combined-probe innovations represent core photoacoustic-imaging patent domains — and the illumination and the detection are the foundational, high-value capabilities. LIGHT-SOURCE / ILLUMINATION PATENTS: the LIGHT delivery — pulsed LASERS (high-power, fast-tunable) and lower-cost ALTERNATIVES (LEDs, laser diodes — enabling cheaper, more portable systems), MULTI-WAVELENGTH illumination ('SPECTROSCOPIC' photoacoustics — multiple colors to distinguish hemoglobin oxygenation and other molecules by their absorption spectra), LIGHT DELIVERY/fluence (getting enough light into tissue), and SAFETY limits (laser exposure limits); light-source/illumination methods are core, high-value, DISTINCTIVE IP (the light source and especially MULTI-WAVELENGTH/spectroscopic illumination (the basis of molecular/functional imaging) are core, contested IP, and low-cost light sources (LEDs/laser diodes replacing expensive lasers) are a key, defensible direction toward affordable, portable photoacoustics). TRANSDUCER / DETECTION PATENTS: the ULTRASOUND DETECTION — TRANSDUCER ARRAYS detecting the weak photoacoustic waves, SENSITIVITY and BANDWIDTH (photoacoustic signals are broadband and weak), ALL-OPTICAL or novel detectors (e.g. optical resonators — high sensitivity without electronics), COMBINED photoacoustic + ULTRASOUND probes (one probe for both — practical and powerful), and NOISE reduction; transducer/detection methods are core, high-value, distinctive IP (sensitive, broadband detection of weak photoacoustic signals — and combined photoacoustic-ultrasound probes — is a key, contested, defensible area, since detection sensitivity directly limits depth and image quality, and novel/all-optical detectors are a frontier). MULTI-WAVELENGTH PATENTS: spectroscopic multi-wavelength illumination for molecular/oxygenation imaging; multi-wavelength methods are high-value IP (multi-wavelength is the basis of functional/molecular photoacoustics). COMBINED-PROBE PATENTS: integrated photoacoustic + ultrasound probes; combined-probe methods are high-value IP (combining PA + US in one probe is practical and clinically powerful). Light-source/illumination, transducer/detection, multi-wavelength, and combined-probe are the highest-value core IP because illumination and detection are exactly what determine photoacoustic imaging's depth, sensitivity, and molecular capability.

Reconstruction/imaging innovations; contrast-agent innovations; system/application innovations; and oxygenation-quantification innovations represent additional photoacoustic-imaging patent domains — and accurate reconstruction, molecular contrast, and clinical systems are where functional imaging and value lie. RECONSTRUCTION / IMAGING PATENTS: RECONSTRUCTING the image — reconstruction ALGORITHMS (turning detected sound into an image), accurately QUANTIFYING OXYGENATION (sO2) and chromophore concentrations (genuinely HARD — the light FLUENCE varies unpredictably with depth, so measured signal ≠ true absorption — 'spectral coloring,' a central quantification problem), ARTIFACT and MOTION correction, and REAL-TIME imaging; reconstruction/imaging methods are core, high-value IP, §101-aware (claim specific technical reconstruction/quantification systems tied to the imaging hardware, not abstract math) — accurate OXYGENATION QUANTIFICATION (correcting for depth-dependent light fluence) is a central, hard, defensible challenge (it's what makes functional photoacoustics trustworthy), along with real-time reconstruction, increasingly AI-assisted. CONTRAST-AGENT PATENTS: CONTRAST AGENTS and molecular probes — exogenous DYES/NANOPARTICLES that absorb strongly at chosen wavelengths to TARGET specific molecules, cells, or tissues (molecular/targeted imaging), activatable probes, and combining with endogenous contrast; contrast-agent methods are core, high-value, DISTINCTIVE IP (targeted CONTRAST AGENTS (and molecular probes) extend photoacoustics from anatomical/functional to MOLECULAR imaging (seeing specific biomarkers) — a rich, defensible area, though agents face their own regulatory/approval path like any injectable). SYSTEM / APPLICATION PATENTS: the SYSTEM and applications — COMBINED photoacoustic-ULTRASOUND systems (leveraging existing ultrasound workflow), HANDHELD/clinical scanners and MICROSCOPY/preclinical systems, and applications (BREAST cancer characterization, OXYGENATION/perfusion mapping, VASCULAR and inflammatory disease (e.g. Crohn's), surgical guidance), plus CLINICAL VALIDATION/regulatory; system/application methods are high-value IP, §101-aware — complete clinical systems (especially combined PA-ultrasound, fitting existing workflows) and validated applications are key value areas, and clinical validation/regulatory clearance is decisive (as for any medical imaging device). OXYGENATION-QUANTIFICATION PATENTS: accurate sO2 measurement correcting for fluence; oxygenation-quantification methods are high-value IP (accurate oxygenation is photoacoustics' signature functional capability). Reconstruction/imaging, contrast-agent, system/application, and oxygenation-quantification are the highest-value application IP because accurate reconstruction, molecular contrast, and clinical systems are exactly what turn the photoacoustic effect into trustworthy, valuable medical imaging.

Photoacoustic imaging startup IP strategy must navigate the functional/molecular-contrast-is-the-unique-value insight (photoacoustics' singular advantage is non-invasive FUNCTIONAL and MOLECULAR contrast at ultrasound DEPTH — especially measuring blood OXYGENATION (sO2) and vascularity, which neither pure ultrasound nor pure optics can do at depth — so position around this unique capability (functional/molecular imaging without radiation), not as a generic imaging method, and target applications where oxygenation/molecular contrast genuinely changes clinical decisions), the oxygenation-quantification-is-a-hard-defensible-problem (accurately QUANTIFYING oxygenation/chromophores is genuinely hard (light fluence varies with depth — 'spectral coloring'), so reconstruction/quantification IP that delivers TRUSTWORTHY oxygenation values is disproportionately valuable, since unreliable quantification undermines the whole value proposition), the combined-PA-ultrasound-eases-adoption (integrating photoacoustics with ULTRASOUND (one probe/system) leverages the huge installed ultrasound base and clinical workflow — combined PA-ultrasound IP is a key, practical, defensible path to adoption (use familiar ultrasound + add functional contrast)), the low-cost-light-source-democratizes (expensive pulsed LASERS are a cost/portability barrier — LOW-COST light sources (LEDs, laser diodes) that enable affordable, portable photoacoustics are a valuable, defensible direction that could broaden the market), the clinical-validation/regulatory-is-decisive (like all medical imaging, photoacoustics lives or dies on CLINICAL VALIDATION and regulatory CLEARANCE (FDA) and reimbursement — patents matter but clinical evidence (that it improves outcomes/decisions) and the regulatory path are equally decisive, and the timeline is long; Seno's breast device shows the path and the difficulty), the contrast-agents-extend-to-molecular-but-add-regulatory (targeted CONTRAST AGENTS unlock MOLECULAR imaging (seeing specific biomarkers) — a high-value, defensible extension, but injectable agents add their own drug-like regulatory burden, so weigh agent vs endogenous-contrast approaches), the detection-sensitivity-and-novel-detectors-frontier (detection SENSITIVITY limits depth and quality — sensitive, broadband, and novel ALL-OPTICAL detectors are a defensible hardware frontier), the application-focus-beats-a-platform (a concrete, validated APPLICATION (breast cancer characterization, inflammatory-disease monitoring, oxygenation in a specific setting) with proven clinical value is more fundable and defensible than a generic photoacoustic platform — own an application with evidence), the §101-and-claim-hardware (reconstruction/quantification and AI are valuable but pure-software/diagnostic-correlation claims face §101 risk — claim the specific technical imaging/reconstruction system or device, not abstract math or 'measure X to diagnose Y'), the academic-roots-and-FTO (photoacoustics has deep academic roots and a growing patent thicket (reconstruction, multi-wavelength, probes) — FTO across illumination/detection/reconstruction/agents matters, and differentiating from foundational academic IP is important), and a landscape where light sources, transducers, reconstruction, contrast agents, and systems are the durable assets; understand that functional/molecular contrast, accurate quantification, combined-ultrasound systems, and clinical validation decide value, so the durable startup IP is in illumination (multi-wavelength/low-cost), detection, reconstruction/quantification, contrast agents, and combined-system applications — with oxygenation quantification, combined PA-ultrasound, low-cost light sources, and the validated application often the real moat, and that image quality/depth, quantification accuracy, clinical validation, and FTO matter as much as patents; identify whitespace in oxygenation quantification, combined PA-ultrasound, low-cost sources, novel detectors, contrast agents, and validated applications. PHOTOACOUSTIC IMAGING STARTUP IP STRATEGY: ILLUMINATION (MULTI-WAVELENGTH/LOW-COST), DETECTION, RECONSTRUCTION/QUANTIFICATION, CONTRAST AGENTS, AND COMBINED-SYSTEM APPLICATIONS ARE THE IP: patent illumination, detection, reconstruction/quantification, contrast agents, and applications — claim hardware/systems (mind §101); FUNCTIONAL/MOLECULAR-CONTRAST-IS-THE-UNIQUE-VALUE: non-invasive functional + molecular contrast at ultrasound DEPTH (oxygenation/vascularity neither pure ultrasound nor pure optics can do at depth) — position around this (functional/molecular without radiation) + target applications where oxygenation/molecular contrast changes decisions; OXYGENATION-QUANTIFICATION-IS-A-HARD-DEFENSIBLE-PROBLEM: accurate sO2/chromophore quantification is hard (fluence varies with depth — 'spectral coloring') — reconstruction/quantification IP delivering TRUSTWORTHY values disproportionately valuable; COMBINED-PA-ULTRASOUND-EASES-ADOPTION: integrating with ULTRASOUND (one probe/system) leverages the huge ultrasound base + workflow — a key practical defensible adoption path; LOW-COST-LIGHT-SOURCE-DEMOCRATIZES: LEDs/laser diodes replacing expensive lasers enable affordable portable photoacoustics — a valuable defensible market-broadening direction; CLINICAL-VALIDATION/REGULATORY-IS-DECISIVE: clinical validation + FDA clearance + reimbursement decisive (patents matter but evidence + regulatory path equally decisive, long timeline — Seno's breast device shows the path/difficulty); CONTRAST-AGENTS-EXTEND-TO-MOLECULAR-BUT-ADD-REGULATORY: targeted agents unlock MOLECULAR imaging (specific biomarkers) — high-value defensible extension but injectables add drug-like regulatory burden (weigh agent vs endogenous-contrast); DETECTION-SENSITIVITY-AND-NOVEL-DETECTORS-FRONTIER: sensitivity limits depth/quality — sensitive broadband + ALL-OPTICAL detectors a defensible hardware frontier; APPLICATION-FOCUS-BEATS-A-PLATFORM: a concrete validated APPLICATION (breast/inflammatory-disease/oxygenation) with clinical value more fundable/defensible than a generic platform; §101-AND-CLAIM-HARDWARE: reconstruction/AI valuable but pure-software/diagnostic-correlation claims face §101 — claim the technical imaging/reconstruction system/device not abstract math or 'measure X→diagnose Y'; ACADEMIC-ROOTS-AND-FTO: deep academic roots + growing patent thicket — FTO across illumination/detection/reconstruction/agents + differentiate from foundational academic IP; IMAGE-QUALITY-DEPTH/QUANTIFICATION-ACCURACY/CLINICAL-VALIDATION/FTO MATTER AS MUCH AS PATENTS: image quality/depth, quantification accuracy, clinical validation, and FTO drive value; WHEN TO PATENT: NOVEL ILLUMINATION/DETECTION/RECONSTRUCTION/AGENT/SYSTEM METHOD WITH DATA: file once a method shows data (depth/resolution + oxygenation/quantification accuracy + sensitivity + real-time performance + clinical/preclinical results) — claim hardware/systems (mind §101); demonstrated depth/quantification accuracy and clinical value are the critical photoacoustic IP metrics; KEY FTO CHECKLIST: Seno Medical/iThera Medical/FUJIFILM-VisualSonics + optoacoustic/medical-imaging companies + foundational academic IP; light source/illumination (pulsed LASERS/low-cost LEDs-laser diodes/MULTI-WAVELENGTH spectroscopic-oxygenation/light delivery-fluence/safety); transducer/detection (transducer arrays/SENSITIVITY-bandwidth-weak signals/ALL-OPTICAL-novel detectors/COMBINED PA+ULTRASOUND probes/noise); multi-wavelength (spectroscopic molecular/oxygenation); combined-probe (PA + ultrasound); reconstruction/imaging (reconstruction algorithms/QUANTIFYING oxygenation-sO2-fluence-correction-'spectral-coloring'/artifact-motion/real-time — §101); contrast agents (targeted DYES-NANOPARTICLES/activatable probes/molecular imaging — regulatory burden); system/application (combined PA-ULTRASOUND/handheld-clinical + microscopy-preclinical/BREAST-OXYGENATION-VASCULAR-inflammatory/clinical validation — §101); oxygenation-quantification (accurate sO2); functional/molecular contrast the unique value; oxygenation-quantification a hard defensible problem; combined-PA-ultrasound eases adoption; clinical validation/regulatory decisive.